Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 31, 2011. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 600,000 Ordinary shares of 25 pence each.
- Purchase Date: August 31, 2011.
- Price Range: Highest price paid was 1,316.5 pence per share; lowest price paid was 1,287.5 pence per share.
- Treasury Holdings: 503,996,816 shares held in Treasury (9.03% of total issued share capital).
- Voting Rights Impact: Including unsettled purchases, Treasury shares represent 9.93% of total voting rights.
- Shares in Issue: 5,077,021,627 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 600,000 repurchased shares. This action increases the percentage of voting rights held in Treasury to 9.93%.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,077,021,627) for calculating disclosure thresholds under FSA rules.
- Confirm the current Treasury share count (503,996,816) and its impact on voting rights (9.93%).
- Note that the repurchased shares are cancelled, permanently reducing the company's share capital.